Michael McCartney
Cancer Genetics has appointed Michael McCartney as chief commercial officer, effective immediately. McCartney was previously CEO of SciKon Innovation, an early-stage life science company. Before that, he was SciKon's COO. He has more than 20 years of experience in the life science space including positions at Roche, Siemens, and Abbott.
Rohan Hastie, John Ryals
Rohan Hastie was named President and CEO of Metabolon. He replaces John Ryals, who retired from those posts, but will remain on the company's board. Ryals has been President, CEO, and a board member of Metabolon since April 2002, when he cofounded the firm.
Hastie joined Metabolon in September 2017 as chief business officer. Before that, he was president of consulting firm Arrow Life Sciences & Healthcare. He also has held leadership positions in diagnostics and corporate development at Hologic, where he was most recently president of Hologic Diagnostic Solutions.
Lawrence Firestone
Akonni Biosystems has appointed Lawrence Firestone to the role of executive VP and CFO to bring the company through the commercialization phase of its business plan. Firestone has previously served as CEO, CFO, and COO in various technology firms.
For more recent items on executive appointments and promotions in the omics and molecular diagnostics industries, please see the People in the News page on our website.